Posts Tagged ‘
Roche ’
Aug 18th, 2009 |
By Patrick Cox |
Category: Stock Market Investing
Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.
Tags: DNA, investing in biotech, Patrick Cox, Pharmaceutical companies, Roche
Posted in Stock Market Investing |
No Comments »
May 6th, 2009 |
By Louis Basenese |
Category: Stock Market Investing
I promise. Alexander Green and I are not in cahoots about the coming boom in corporate takeovers… We both researched the possibility separately. Unprompted, I might add. And yet, armed with different evidence, we arrived at the same conclusion. If you ask me, such a convergence of analysis in a narrow space of time shouldn’t be ignored. So today, let’s move on from why a takeover boom is imminent and focus exclusively on three takeover targets you can profit from…
Tags: APC, CRXL, CSCO, DNA, GILD, investing in biotech, Lou Basenese, LWSN, NVS, ORCL, Pfe, Roche, Sgp, SNY, WYE
Posted in Stock Market Investing |
No Comments »
Apr 27th, 2009 |
By Andrew Snyder |
Category: Stock Market Investing
The pig flu is scaring the wits out of travelers across the globe. While a handful of companies are enjoying surging share prices today, the biggest winners will be the news networks that are blowing the whole thing out of proportion.
Tags: Andrew Snyder, GILD, GSK, NVAX, Roche
Posted in Stock Market Investing |
No Comments »
Aug 23rd, 2008 |
By John Stepek |
Category: Politics & Economics
There’s a merger boom going on right now, but amid all the gloom, no one’s really paying much attention.
Tags: , ACM, Axa Framlington Biotech fund, Bmy, DNA, John Stepek, OXB, PTI, Roche, UK stocks
Posted in Politics & Economics |
No Comments »
Jul 25th, 2008 |
By Rob Fannon |
Category: Featured, Financial News
Swiss drug company Roche (OTC:RHHBY) may not get its hands on San Francisco-based biotech outfit Genenetech (NYSE:DNA) as quickly as it had hoped.
Genetech has formed a special committee of independent directors to evaluate the $89-a-share acquisition offer from Roche, which already owns 56 percent of the US biotech firm.
If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…
While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry… and its investors.
With Genentech…
Tags: BIIB, DNA, ELN, Genentech, GENZ, investing in biotech, RHHBY, Rob Fannon, Roche
Posted in Featured, Financial News |
No Comments »
May 27th, 2008 |
By Theo Casey |
Category: International Investing
Bowing to peer pressure from Eurocentric readers, today’s comment focuses squarely on opportunities in European indexes, or should that be ‘bourses.’
Tags: , Bear Run, Berkshire Hathaway, Cac 40, DAX, Deutsche Bank, euro, Euro Zone, European Indexes, European Stocks, German Stocks, InBev, International Investing, Ipo, Nokia, Recovery Stocks, Roche, SAP, Ubs, Warren Buffett
Posted in International Investing |
No Comments »